Interestingly, in two small studies, those with metabolic comorbidities treated with a FAE showed improvement in metabolic syndrome-associated biomarkers 27 and in endothelial function
In the TRIUMPH-4 Phase 3 trial, the most common adverse events for the 12 mg dose were nausea (43.2%), diarrhea (33.1%), constipation (25.0%), vomiting (20.9%), and decreased appetite
While not all autoimmune conditions can be completely reversed, many patients experience significant improvements in symptoms, inflammatory markers, and disease activity through properly implemented functional medicine protocols that address their specific underlying imbalances
Phase 3 trials, such as TRANSCEND-T2D-1, have demonstrated clinically meaningful outcomes
FabiABhargavaRFatigoniSGuglielmoMHorneberMRoilaFet al
It helps modulate the brains reward system, reducing the urge for compulsive eating and supporting long-term behavior change